Impact of Patient Mild Cognitive Impairment on Physician Decision-Making for Treatment

Emilie M Blair1,2, Darin B Zahuranec3, Kenneth M Langa2,4,5,6

  • 1University of Michigan (U-M), Ann Arbor, MI, USA.

Abstract

Insights

Physician assumptions about mild cognitive impairment (MCI) influence treatment decisions, often leading to less evidence-based care for these patients. Understanding these biases is crucial for improving treatment access for individuals with MCI.

Area of Science:

  • Geriatric Medicine
  • Cognitive Neurology
  • Medical Decision-Making

Background:

  • Older adults with mild cognitive impairment (MCI) should receive evidence-based treatments.
  • Patients with MCI are less likely to receive recommended treatments compared to cognitively normal individuals.

Purpose of the Study:

  • To investigate how a mild cognitive impairment (MCI) diagnosis affects physician decision-making regarding patient treatment.
  • To identify physician assumptions influencing treatment recommendations for patients with MCI.

Main Methods:

  • Qualitative study involving semi-structured interviews with 18 physicians across cardiology, neurology, and internal medicine.
  • Analysis of physician decisions concerning surgery, invasive/non-invasive tests, rehabilitation, and preventive medication.
  • Qualitative content analysis to identify key themes in physician decision-making.

Main Results:

  • Physicians reported that MCI influenced recommendations for treatments or tests.
  • Two primary themes emerged: assumptions about MCI patients' cognitive abilities impacting treatment adherence and assumptions about poor health status affecting treatment tolerance.
  • Physician beliefs included impaired decision-making, poor adherence, communication difficulties, and increased treatment risks for MCI patients.

Conclusions:

  • A patient's MCI diagnosis significantly impacts physician treatment decisions.
  • Some physician assumptions about MCI patients are not supported by evidence.
  • These physician biases may explain the underutilization of effective treatments and tests in patients with MCI, highlighting a need for improved physician understanding and decision-making interventions.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
95
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
120
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
608
Pharmacodynamics in Geriatric Patients: Effects of Age01:27

Pharmacodynamics in Geriatric Patients: Effects of Age

Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
106
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.3K
Ethical Issues01:27

Ethical Issues

Nurses are essential in patient care, upholding the ethical principles of their profession and effectively navigating ethical dilemmas. Neglecting ethical issues can lead to inadequate patient care, compromised therapeutic relationships, and moral distress among healthcare workers.
Ethical Concerns in Healthcare:
1.6K